Biomarkers of pembrolizumab response in head and neck cancer

Bookmark and Share
Published: 25 Apr 2018
Views: 4486
Dr Tanguy Seiwert - The University of Chicago Medicine, Chicago, USA

Dr Seiwert speaks with ecancer at AACR 2018 about potential biomarkers to predict patients with head and neck squamous cell carcinoma (HNSCC) responses to pembrolizumab.

He highlights markers derived from trial cohorts of over 200 patients, noting tumour mutational burden (TMB), PD-L1 expression and T-cell activated gene expression profile (GEP) as effective predictive markers for patients when use individually, or in combination.